摘要PET绝对定量心肌血流（MBF）显像在冠心病的诊断、危险分层和预后评估方面均具有重要的临床增益价值，但由于传统正电子心肌灌注显像剂的限制，其尚未在临床上广泛应用。2-叔丁基-氯-5[4-(2-氟- 18F-乙氧基甲基）苯基甲氧基]-3(2H)-哒嗪酮（ 18F-Flurpiridaz）的成功研发开创了正电子心肌灌注显像剂的新领域，其具有良好的绝对定量MBF和心肌血流储备的性能，且相较于经典的正电子心肌灌注显像剂，其在物理性质、心肌摄取率和临床应用的方便性等方面具有明显优势，目前已进入临床Ⅲ期研究，成为最有前景的 18F标记的PET心肌灌注显像剂。笔者就 18F-Flurpiridaz PET绝对定量MBF显像的研究进展进行综述。

abstractsPET absolute quantitative myocardial blood flow (MBF) imaging has significant clinical incremental value in the diagnosis, risk stratification, and prognosis evaluation of coronary artery disease. Still, it has not been widely used in the clinic due to the limitation of conventional positron myocardial perfusion imaging agents. The successful development of 2-tert-butylchloro-5[4-(2-fluoro- 18F-ethoxymethyl) phenyl methoxy]-3(2H)-pyridazine ketone ( 18F-Flurpiridaz) has pioneered a new field of positron myocardial perfusion imaging agents. It has excellent absolute quantitative property in MBF and myocardial flow reserve and has obvious advantages over traditional positron myocardial perfusion imaging agents in physical properties, myocardial extraction rate, and application convenience in the clinic, also, it has entered clinical phase Ⅲ research process and has become the most promising 18F-labeled PET myocardial perfusion imaging agents. The authors review the research progress in 18F-Flurpiridaz PET absolute quantitative MBF imaging.